Wanjia (HKG:0401) incurred an attributable loss of HK$712,000 in the six months ended Sept. 30, compared with an attributable profit of HK$1.3 million a year prior, a Wednesday Hong Kong bourse filing said.
Loss per share in the interim period was HK$0.0013, whereas the company had made earnings per share of HK$0.0022 in the year-ago period.
The pharmaceutical distribution company's revenue jumped 2.4% to HK$85.7 million in the fiscal first half from HK$83.7 million previously, driven by a higher revenue from the Hemodialysis business wing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.